Cardiovascular diseases in Belgium: sugar, platelets, TXA2, and ginger (2025)

Belgian Cardiovascular Epidemiology

• ~30% of deaths in Belgium = CVDs (Sciensano 2024)
• ~700 new heart attacks/week in Belgium
• Direct medical cost of CVDs: ~3 billion €/year
• Number 1 modifiable risk factors: dyslipidemia, HBP, diabetes, smoking, sedentary lifestyle
• Average Belgian sugar consumption: 95g/day (2× WHO recommendation)

Molecular Mechanisms: Sugar and Vascular Pathology

1. TXA2 and Platelet Activation

Thromboxane A2 (TXA2) is the key mediator of platelet aggregation:

• Hyperglycemia → platelet PKC activation → TXA2 ↑
• TXA2 → TP receptors on platelets → aggregation amplification → thrombotic risk
• TXA2 → vasoconstriction → coronary/cerebral ischemia
• Fructose → ginger uric acid → xanthine oxidase → ROS → TXA2 ↑ (indirect mechanism)
• GIMBER (~35g sugar/100ml) × 3 servings/day = major glycemic load → chronically elevated TXA2

2. Endothelial NF-κB and Atherosclerosis

Endothelial NF-κB is the driver of atherosclerosis:

• AGE → RAGE → NF-κB in endothelial cells → ICAM-1, VCAM-1, E-selectin
• Monocytes → endothelial adhesion via ICAM-1/VCAM-1 → transmigration → intimal macrophages
• Macrophages → foam cells (cholesterol-ldl-reduire-naturellement">oxidized LDL phagocytosed) → fatty streaks → atheromatous plaque
• NF-κB → MMP-9 → fibrous cap destabilization → vulnerable plaque → ACS (acute coronary syndrome)
• NF-κB → tissue factor → intrinsic coagulation initiation

3. eNOS and Endothelial Dysfunction

eNOS (endothelial Nitric Oxide Synthase) is inhibited by sugar:

• Hyperglycemia → O-GlcNAc modification of eNOS → activity ↓ → NO ↓
• Fructose → uric acid → eNOS → uncoupling → superoxide instead of NO (oxidative paradox)
• AGE → RAGE → NADPH oxidase → ROS → NO quenching (chemical destruction of NO)
• NO ↓ → vasoconstriction → HBP → accelerated atherosclerosis → vicious circle
• NO ↓ → facilitated platelet aggregation (NO normally inhibits platelets)

4. Fibrinolysis and Coagulation

• Hyperglycemia → PAI-1 (plasminogen activator inhibitor) ↑ → fibrinolysis ↓
• PAI-1 ↑ → less clot dissolution → chronic thromboembolic risk
• Fibrinogen ↑ (acute phase protein) with chronic NF-κB → blood hyperviscosity
• Von Willebrand factor ↑ (endothelial NF-κB) → platelet adhesion ↑

Ginger and Cardioprotection: Scientific Data

6-Gingerol and Platelets

• 6-gingerol → platelet COX-1 inhibition → TXA2 ↓ → mild antiplatelet
• Ginger → ↑ prostacyclin (PGI2, vasodilator and antiplatelet) → improved TXA2/PGI2 balance
• Clinical study (Verma 2004): 5g ginger/day → ↓ ADP-induced aggregation in healthy subjects

Ginger and eNOS

• 6-gingerol → PI3K/Akt activation → eNOS Ser1177 phosphorylation → activated eNOS → NO ↑
• Ginger → Nrf2 → HO-1 → biliverdin (antioxidant) → NO protection against ROS degradation

⚠️ Critical Anticoagulant Interaction

Ginger has mild antiplatelet properties. In combination with:

• Aspirin/clopidogrel/ticagrelor → increased bleeding risk → mandatory cardiology advice
• Warfarin/acenocoumarol/rivaroxaban/apixaban → anticoagulant potentiation → INR to monitor
• Always inform your cardiologist or general practitioner